Le Lézard
Classified in: Health, Science and technology
Subjects: PDT, PET, ANW

Neogen launches new preventative care DNA test, Igenity® Canine Wellness


LINCOLN, Neb., Dec. 8, 2020 /PRNewswire/ -- Neogen Corporation (Nasdaq: NEOG) announced today that it has launched Igenity® Canine Wellness, a preventative care DNA screening tool for veterinarians.

Genetic background can influence health, physical traits and behavior in dogs. Igenity Canine Wellness addresses this by predicting a percentage of the heritable component for relatively common, actionable diseases. Awareness of genetic risks allows veterinary professionals to make more informed recommendations on diet, diagnostic screening, and lifestyle to enable a longer and happier life for each pet and their family.

"Veterinary professionals can use the knowledge of predisposed risk factors in providing client education and making personalized recommendations related to diet, exercise, and diagnostic screening tests, such as ultrasound or blood work to detect possible health concerns," said Lindsey Kock, DVM, Neogen's companion animal market development manager. "Igenity Canine Wellness results will help doctors and staff provide better care for patients in the hospital and equip pet parents to anticipate and prevent health challenges in the future."

During a veterinary exam, a staff member will use a cytology swab from an Igenity Canine Wellness kit to collect cheek cells from the patient's mouth. When the veterinary hospital has finished preparing the samples, the kit box is then sent to Neogen Genomics lab for processing. The practice will then receive a genetic risk report that then can be communicated to the pet parent to create a wellness journey to best benefit their canine's health needs.

Scientists have discovered a great deal since the dog genome was first sequenced in 2004 about the genetics of disease susceptibility, underpinnings of physical traits and even behavior.  Much of this research has been driven by studies that utilize non-invasive DNA samples from dogs to investigate the genetic underpinnings of the over 450 potential models for human disease.

"We are just scratching the surface on the underlying genetics in dogs of common conditions such as cancer, allergies, osteoarthritis, obesity and behavior," said Kock. "The DNA targets for Igenity Canine Wellness are based on published research for common, actionable conditions diagnosed in veterinary medicine."

"Our genomics team continues to innovate by providing solutions that improve the health and well-being of the animals we care so much for," said John Adent, Neogen's president and chief executive officer. "Igenity Canine Wellness will help veterinarians provide a genetic map to pet parents and aid in their quality of service, as well as a dog's life."

For more information on Igenity Canine Wellness and list of conditions covered go to www.neogen.com/igenity-canine-wellness/.

Neogen Corporation develops and markets products dedicated to food and animal safety. Neogen's worldwide genomics operations deliver innovative, affordable DNA testing for the discovery and commercial application of genomic advances that enhance the safety and abundance of life. DNA testing services are provided for food safety, animals, aquaculture, agronomy, forestry and horticulture, as well as supporting the research institutions and organizations serving these industries. See more at www.neogen.com.

CONTACTS:

Product: Lindsey Kock, [email protected]


Media: Clint Mefford, [email protected]

 

SOURCE Neogen Corporation


These press releases may also interest you

at 16:05
Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today...

at 16:05
Biodesix, Inc. , a leading diagnostic solutions company with a focus in lung disease, today announced its financial and operating results for the first quarter ended March 31, 2024, and provided a corporate update. "I am very pleased to announce...

at 16:05
Arcus Biosciences, Inc. , a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the first quarter ended March 31, 2024,...

at 16:05
Consensus Cloud Solutions, Inc. today reported financial results for the first quarter of 2024. "I am pleased with our Q1 performance. SoHo and Corporate revenues were ahead of expectations, which combined with our cost saving measures, produced a...

at 16:05
Porch Group, Inc. ("Porch Group" or "the Company") , a homeowners insurance and vertical software platform, today reported first quarter results through March 31, 2024, with total revenue of $115.4 million, which increased 32% compared to the prior...

at 16:05
Mind Medicine (MindMed) Inc. , (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its financial results for the quarter ended March 31, 2024,...



News published on and distributed by: